PDC*line Pharma Company

PDC*line Pharma develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells.
Technology: Dendritic Cells
Industry: Tumor-Specific Antigens, Whole-Cell Antigens
Headquarters: La Tronche, Rhone-Alpes, France
Founded Date: 2014-04-01
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 10
Total Funding: 39902600
Estimated Revenue: $1M to $10M
Last Funding Date: 2021-12-06
Last Funding Type: Series B

Visit Website
contact@pdc-line-pharma.com
Register and Claim Ownership